Albany Molecular Research (AMRI) & Its Competitors Head-To-Head Comparison
Albany Molecular Research (NASDAQ: AMRI) is one of 197 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Albany Molecular Research to similar businesses based on the strength of its valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.
This table compares Albany Molecular Research and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Albany Molecular Research||-5.93%||-13.39%||-3.42%|
|Albany Molecular Research Competitors||-3,992.03%||-120.41%||-44.59%|
Valuation & Earnings
This table compares Albany Molecular Research and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Albany Molecular Research||$680.81 million||$73.33 million||-12.08|
|Albany Molecular Research Competitors||$207.78 million||-$2.31 million||0.51|
Albany Molecular Research has higher revenue and earnings than its rivals. Albany Molecular Research is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and price targets for Albany Molecular Research and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Albany Molecular Research||0||4||0||0||2.00|
|Albany Molecular Research Competitors||474||2249||6143||119||2.66|
Albany Molecular Research currently has a consensus target price of $18.00, indicating a potential downside of 17.20%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.54%. Given Albany Molecular Research’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Albany Molecular Research has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
72.1% of Albany Molecular Research shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.5% of Albany Molecular Research shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Albany Molecular Research has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Albany Molecular Research’s rivals have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.
Albany Molecular Research beats its rivals on 7 of the 12 factors compared.
About Albany Molecular Research
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.